Adipose tissue–derived multi-lineage progenitor cells improve left ventricular dysfunction in porcine ischemic cardiomyopathy model

Shudo, Yasuhiro; Miyagawa, Shigeru; Ohkura, Hanayuki; Fukushima, Satsuki; Saito, Atsuhiro; Kawaguchi, Naomasa; Matsuura, Nariaki; Toda, Köichi; Sakaguchi, Taichi; Nishi, Hiroyuki; Yoshikawa, Yasushi; Shimizu, Tatsuya; Okano, Teruo; Matsuyama, Akifumi; Sawa, Yoshiki

doi:10.1016/j.healun.2016.11.012

Cited by 7 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the control group, however, this parameter worsened over the entire study period up to 12 weeks. In the early period after transplantation, there were no significant differences in the diastolic dimensions of the left ventricle, but subsequently, diastolic dysfunction progressed in the control group, whereas this parameter did not change significantly after cell transplantation [129,153].…”

Section: Adipose-derived Stem Cells (Ascs)mentioning

confidence: 88%

Stem cell therapy for cardiac regeneration: key points

Kyryk

2024

COT

View full text Add to dashboard Cite

Cardiovascular diseases are a leading cause of disability and mortality among the working population, necessitating the development and implementation of new, more effective treatment and rehabilitation methods for such patients, including the use of modern cellular and tissue technologies. In this review, an analysis and summary of research results over the past decades regarding the effectiveness of various types of stem cells in heart pathology were conducted. Priority directions include the search for more accessible and safe sources of stem cells, the development of new effective methods for their cultivation, and the use of scaffolds for transplantation. Given the pathogenetic mechanisms of cardiovascular pathology and myocardial regeneration, particular interest for clinical application is drawn to tissue-specific progenitors from the myocardium for replacing injured cardiomyocytes, endothelial progenitors for correcting accompanying endothelial dysfunction, and multipotent mesenchymal cells of various origins with low immunogenicity that exhibit trophic, anti-inflammatory, immunomodulatory, and anti-apoptotic effects. Questions regarding the optimal method, dose, and frequency of stem cell administration, as well as the standardization of criteria for their quality and effectiveness, remain open. Additionally, the combined use of different types of stem cells may serve as a new priority strategy in assessing the effectiveness and safety of cell therapy, especially considering the paradigm of repeated transplantation. The successful translation of obtained preclinical results into further large, well-planned, placebo-controlled clinical trials will enhance the safety and effectiveness of cell therapy for cardiovascular diseases, which is one of the current challenges of modern regenerative medicine.

show abstract